GlassScriptPhysician profile
Lisa M Coram
NPI 1215197926
$4,526.40
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,184 · 2020: $810 · 2021: $1,280 · 2022: $776 · 2023: $306 · 2024: $171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $476.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $632.08 | 2020-2024 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $624.75 | 2019-2024 | Rexulti, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $470.14 | 2019-2024 | Austedo Xr, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $456.05 | 2019-2023 | Trintellix |
| Janssen Pharmaceuticals, INC | $398.13 | 2019-2022 | |
| Lundbeck LLC | $390.32 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $333.92 | 2019-2021 | |
| Allergan, INC. | $260.22 | 2019-2020 | |
| Abbvie INC. | $196.09 | 2021-2024 | Vraylar |
| Avanir Pharmaceuticals, INC. | $103.66 | 2019-2022 | |
| Shire North American Group INC | $95.75 | 2019 | |
| Alkermes, INC. | $92.82 | 2021-2023 | Lybalvi |
| Neurocrine Biosciences, INC. | $92.52 | 2019-2023 | Ingrezza |
| Livanova USA, INC. | $88.12 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $57.26 | 2020-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $41.59 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $34.24 | 2022-2023 | Sunosi |
| Ironshore Pharmaceuticals INC. | $28.56 | 2019 | |
| Neos Therapeutics, LP | $28.36 | 2019 | |
| Corium, LLC | $24.17 | 2023 | Azstarys |
| Neuronetics, INC. | $20.78 | 2019-2021 | |
| Bausch Health US, LLC | $15.46 | 2021 | |
| Tris Pharma INC | $14.23 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.06 | 2019 | |
| Alfasigma USA, INC. | $13.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Coram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.